Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pfs25m-epa
- Development stage
- Phase 1
- Lead developer
- National Institutes of Health
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Pfs25M-EPA is a malaria transmission-blocking vaccine candidate consisting of a recombinant form of Plasmodium falciparum surface protein Pfs25 (specifically the Pfs25M variant) chemically conjugated to ExoProtein A (EPA), a recombinant mutant and detoxified protein from Pseudomonas aeruginosa. The Pfs25M variant was developed to remove heterologous amino acid residues present in an earlier version (Pfs25H). This vaccine is designed to interrupt the malaria parasite's life cycle by targeting sexual stage development in mosquitoes, specifically zygotes and ookinetes.
- Other names
- Pfs25M-EPA/Alhydrogel
02
Targets
Pfs25
Beyond the preview
Go deeper on pfs25m-epa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pfs25m-epa.